# Cris De Luca

> Cris De Luca is a Series A investor at Sanofi Ventures (Cambridge) backing Health Care and Medical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures)
- Location: Cambridge, United States
- Total investments: 7
- Last investment: Aug 2026
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/crisdeluca
- X (Twitter): http://twitter.com/crisdeluca

Cris De Luca is a Series A investor at Sanofi Ventures in Cambridge focused on Health Care and Medical. Cris joined Sanofi Ventures in 2020 with a 15+ year track record of building and launching emerging technologies, startups and innovation platforms for some of the largest organizations in the world. Prior to Sanofi, Cris was a founding team member of J&J Innovation and Global Head of Digital Innovation since 2013. He held primary digital anddata responsibilities, driving strategy and external tech collaborations throughout J&J’s Innovation Centers, JLABS incubators and JJDC corporate ventures across the Pharmaceutical, Consumer and Medical Device businesses.Previously, Cris led emerging technology programs within research informatics at Novartis Institutes for BioMedical Research for six years. With entrepreneurial DNA, Cris is well recognized for his role in the innovation economy since Co-Founding one of the largest startup venture pitch accelerators in the U.S called Ultra Light Startups, accelerating hundreds of companies in Boston, New York City and Silicon Valley, with several large-scale acquisitions by major tech companies. Cris was named a 40 under 40 Innovator by the Boston Business Journal in 2015, and Top 40 Healthcare Transformer by MM&M Magazine in 2019.Cris currently serves on the board of Click Therapeutics as well as the advisory boards of the American Telemedicine Association, SXSW Health, Voice by Amazon Alexa and the Boston University SPH Innovation Hub.Cris holds a MSc in Computer Information Systems from Boston University and a BS in Business Administration from Suffolk University

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 57% |
| Medical | 2 | 29% |
| Machine Learning | 2 | 29% |
| Artificial Intelligence | 2 | 29% |
| mHealth | 1 | 14% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Series B | 2 | 29% |
| Series C | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 57% |
| Israel | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| QuantHealth | Quant Health offers drug simulation, computational biology, clinical data science, respiratory, trial simulation, and oncology services. | $45M | Series B | Aug 04, 2026 |  |
| BranchLab | BranchLab makes healthcare advertising better so that people may find the best healthcare options. | $28.8M | Series A | May 13, 2026 |  |
| Trial Library | Trial Library is an oncology clinical trials company. | $10M | Series A | Dec 02, 2025 |  |
| QuantHealth | Quant Health offers drug simulation, computational biology, clinical data science, respiratory, trial simulation, and oncology services. |  | Venture - Series Unknown | Oct 01, 2025 |  |
| Empatica | Empatica designs and develops AI-enabled wearables, software, and digital biomarkers, to push the boundaries in health monitoring, forecasting, treatment, and research. Empatica’s platform uses a combination of biosensors to detect unique components of human physiology: providing AI-enabled tools advancing the forecasting, monitoring, research, andtreatment of multiple conditions. | $25.9M | Series B | Aug 02, 2022 |  |
| Nucleai | Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects. | $33M | Series B | Mar 22, 2022 |  |
| Medisafe | Medisafe is a digital patient engagement platform, empowering patients to stay on top of all their medications. Its approach leverages the billions of data points collected to personalize patient engagement and improve adherence and persistence to medications.By addressing the major challenges of medication management utilizing a datascience-driven approach, Medisafe improves patient adherence and quality of care. The company provides its pharma and payer partners the opportunity to engage each patient on an individual level, supporting them throughout the entire patient journey, and provides unique insights on behavior patterns critical for improving the patient experience. Medisafe had shown over numerous studies, both retrospective with tens of thousands of patients as well as RCTs, that its solutions improve adherence by up to 20%.Founded following an accidental insulin overdose of the founder's father, the Medisafe solution currently has nearly 5 million registered users across iOS and Android smartphones, tablets, wearables, and Web solutions, who have recorded over 2 billion medication doses. Nearly 200,000 users have rated the app an average of 4.7 out of 5 stars in the App Store and Google Play store, making it the Top Rated solution in the category. Their accolades include Gartner Cool Vendors, Traction winner (Health 2.0 startup competition), Fast Company Most Innovative in Healthcare, Google and Apple Editors' Choice and Top Developer, etc. | $30M | Series C | Feb 25, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund, 2 deals together
- [S32](https://shizune.co/investors/profile/section-32) — VC Fund, 2 deals together
- [7wire Ventures](https://shizune.co/investors/profile/7wire-ventures) — VC Fund, 1 deal together
- [Accenture Ventures](https://shizune.co/investors/profile/accenture-ventures) — VC Fund, 1 deal together
- [AIX Ventures](https://shizune.co/investors/profile/aix-ventures) — VC Fund, 1 deal together
- [ALIVE Israel HealthTech Fund](https://shizune.co/investors/profile/alive-israel-healthtech-fund) — VC Fund, 1 deal together

## About Sanofi Ventures

VC Fund · Cambridge, United States

Sanofi Ventures is the corporate venture capital arm of Sanofi. We have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potentialcures in other core areas of Sanofi’s business footprint, and digital health and data science solutions.

5 contacts available at Sanofi Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Christopher Gagliardi | Principal | https://shizune.co/investors/profile/christopher-gagliardi |
| Alan Walts | Managing Director | https://shizune.co/investors/profile/alan-walts-d3ea |
| Alba Zurriaga Carda | Director of Investments | https://shizune.co/investors/profile/alba-zurriaga-carda |
| Charles Thyne | Industrial Operations | https://shizune.co/investors/profile/charles-thyne |
| Cris De Luca | Partner, Digital Investments, Sanofi Ventures | https://shizune.co/investors/profile/cris-de-luca |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Cris De Luca invest in?

Cris De Luca invests primarily in Health Care, Medical and Machine Learning startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Cris De Luca last invest?

The most recent investment recorded for Cris De Luca closed in Aug 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co